Please ensure Javascript is enabled for purposes of website accessibility

Why Amicus Therapeutics, Inc. Jumped Higher Today

By Brian Orelli, PhD - Mar 1, 2017 at 3:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech could benefit from a softer FDA.

What happened

Amicus Therapeutics (FOLD 1.74%) ended the day up 17%, after the company's CEO John Crowley and his daughter Megan (who has Pompe disease) were highlighted during President Donald Trump's address to Congress last night.

The biotech also announced fourth-quarter earnings this morning, highlighting the company's launch of Galafold in the EU.

Doctor listening to a child's chest with a stethoscope

Image source: Getty Images.

So what

Crowley started Novazyme Pharmaceuticals, later acquired by Genzyme, to develop the drug Myozyme to help his daughter's condition. The President used Crowley's story as an example of how "our slow and burdensome approval process at the Food and Drug Administration keeps too many advances, like the one that saved Megan's life, from reaching those in need."

It's debatable whether the FDA actually held up development of Myozyme -- the drug was approved based on uncontrolled clinical trials in just a handful of patients -- but Crowley's new company, Amicus Therapeutics, is certainly running into roadblocks at the FDA. The agency wants more data before approving Galafold, the biotech's treatment for a rare condition called Fabry disease.

Meanwhile, European regulators have already approved Galafold. During its earnings report, Amicus said 75 patients were on Galafold, and the company believes it can bring the total up to 300 by the end of this year.

Now what

The President's comments could mean that the FDA will become softer, but even if the agency makes a general shift toward reducing efficacy requirements to speed drug development, there are no guarantees that change will apply to Galafold specifically.

At this point, the safest bet is for investors to value Amicus on potential sales in the EU and Japan, where an application should be submitted in the first half of this year. If U.S. sales come earlier than expected, that will offer more upside.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amicus Therapeutics, Inc. Stock Quote
Amicus Therapeutics, Inc.
$11.12 (1.74%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.